Cargando…
Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin: A subanalysis from a randomized, placebo‐controlled trial (RELEASE study)
Angiogenic T (Tang) cells are mediators of vascular repair, and are characterized by surface expression of CXCR4. This receptor for stromal cell‐derived factor‐1α (SDF‐1α) is cleaved by dipeptidyl peptidase‐4 (DPP‐4). Tang cell levels were investigated in people with type 2 diabetes mellitus (T2DM)...
Autores principales: | de Boer, Stefanie A., Reijrink, Melanie, Abdulahad, Wayel H., Hoekstra, Elisa S., Slart, Riemer H. J. A., Heerspink, Hiddo J. L., Westra, Johanna, Mulder, Douwe J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317866/ https://www.ncbi.nlm.nih.gov/pubmed/32166899 http://dx.doi.org/10.1111/dom.14024 |
Ejemplares similares
-
Plasma Nitrate Levels Are Related to Metabolic Syndrome and Are Not Altered by Treatment with DPP-4 Inhibitor Linagliptin: A Randomised, Placebo-Controlled Trial in Patients with Early Type 2 Diabetes Mellitus
por: Reijrink, Melanie, et al.
Publicado: (2021) -
The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018) -
Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
por: Gallwitz, Baptist
Publicado: (2012) -
Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019) -
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
por: Terawaki, Yuichi, et al.
Publicado: (2014)